Search

Saved articles

You have not yet added any article to your bookmarks!

Newsletter image

Subscribe to the Newsletter

Join 10k+ people to get notified about new posts, news and tips.

Do not worry we don't spam!

Novo Nordisk Stock Soars Following FDA Endorsement of Weight-Loss Pill

Novo Nordisk Stock Soars Following FDA Endorsement of Weight-Loss Pill

Post by : Saif Rahman

Shares of the Danish pharmaceutical company Novo Nordisk experienced a significant increase on Tuesday following the approval of its new weight-loss pill by U.S. health regulators. The stock surged approximately 7.5% in early trading, indicating strong investor confidence in the potential of oral treatments for obesity.

The endorsement from the U.S. Food and Drug Administration (FDA) grants Novo Nordisk a prime position in the expanding weight-loss market. Historically, effective obesity treatments have relied on weekly injections, which many individuals find uncomfortable. The new pill is expected to attract those seeking a more convenient weight management option.

Novo Nordisk is recognized for its injectable weight-loss medication, Wegovy, which was introduced in 2021. Despite high demand for Wegovy, the company initially encountered supply shortages. This time around, company officials have assured that they are well-prepared, claiming to have ample stock of the new pill and a strong strategy for a smooth launch in the United States.

Recently, Novo Nordisk has been under pressure due to a decline in market share, particularly from U.S. competitor Eli Lilly. Lilly's injectable drug, Zepbound, has seen a rise in popularity and currently leads in weekly prescriptions within the U.S. Novo Nordisk’s stock had plummeted over 50% earlier this year, making the FDA approval a crucial lifeline.

Analysts suggest that the pill may provide Novo Nordisk with a temporary edge, as many patients are likely to prefer pills to injections due to needle aversion. Nonetheless, experts caution that this advantage might not be enduring, as Eli Lilly is also working on an oral weight-loss drug expected to seek approval by 2026.

Healthcare investors speculate that oral medications might expand the overall market rather than replace injections, with many adults delaying treatment simply due to aversion to injections. However, experts also express concerns that pills may lack the potency of injectable medications, possibly limiting their effectiveness for certain patients.

Financial projections for the new oral drug are optimistic, with some analysts forecasting annual global sales to reach billions, which could help Novo Nordisk counter potential challenges like decreasing drug prices and increasing market competition by 2026.

On Tuesday, Novo Nordisk's shares were among the top gainers in European exchanges, while shares of Eli Lilly saw a minor decline. The approval illustrates the fierce competition within the obesity treatment sector as pharmaceutical companies strive to provide safer, more user-friendly, and effective treatments for millions globally.

Dec. 23, 2025 3:01 p.m. 283

#Global News

Klang Flash Floods Disrupt Traffic Across Selangor, Malaysia
Nov. 18, 2026 11:37 a.m.
Heavy rain causes Klang flash floods, disrupting traffic in Bukit Raja and Shah Alam as motorists face delays across Selangor, Malaysia
Read More
Xi Jinping Urges Asia-Pacific Nations to Remove Trade Barriers
Nov. 18, 2026 10:20 a.m.
Xi Jinping urges Asia-Pacific economies to remove trade barriers, boost investment and strengthen regional stability at the APEC Summit in China
Read More
Singapore Reviews New US Chip Export Controls Targeting China
Nov. 17, 2026 11:34 a.m.
Singapore reviews US chip export restrictions targeting China's AI access, raising concerns for semiconductor trade and data centre businesses
Read More
APEC Members Emphasise Safe and Responsible Use of Artificial Intelligence
Nov. 17, 2026 10:24 a.m.
APEC members discuss responsible AI use, digital innovation and data governance as China and the US compete for global AI leadership
Read More
Union of European Clubs Challenge UEFA and EFC Over EU Competition Rules
Nov. 16, 2026 5:18 p.m.
UEC files an EU competition complaint against UEFA and EFC, challenging club representation, governance rights and decision-making powers
Read More
US Dollar Extends Rally as Yen Faces Pressure After Weak GDP
Nov. 16, 2026 4:29 p.m.
The US dollar reaches a 19-month high as traders assess Fed rate signals, weak Japan GDP data and possible yen intervention
Read More
Sheikh Hasina Plans December Return to Bangladesh Despite Death Threat
Nov. 16, 2026 3:35 p.m.
Sheikh Hasina plans to return to Bangladesh in December despite death threats, a death sentence and growing political tensions with Dhaka
Read More
Trump Plans to Name Nvidia and AI Firms US National Champions
Nov. 16, 2026 10:01 a.m.
Trump administration plans to name Nvidia, Amazon, Microsoft and OpenAI among US AI national champions to expand overseas and compete with China
Read More
Mohammed Shami Retires From Test Cricket, Eyes White-Ball Career
Nov. 7, 2026 11:10 a.m.
Mohammed Shami retires from Test cricket after 13 years, with 229 wickets. He will continue playing white-ball cricket and domestic matches
Read More
Trending News